PMD Act + research peptides — Japan's strict pharmaceutical-import framework
Japan's Pharmaceutical and Medical Devices Act (the PMD Act, 薬機法; full text on e-Gov) requires the Minister of Health, Labour and Welfare's approval for each product before a medicine is manufactured and marketed (Article 14), and only licensed businesses may import medicines for sale (Japan Customs). Research peptides without Japanese approval are unapproved medicines wherever they fall within the Act's definition of a medicine. Individuals may import medicines for their own use within set quantities; above them an import confirmation certificate (輸入確認証) is needed, which replaced Yakkan Shoumei on 1 September 2020. This article documents the framework and the practical implications for Japanese researchers. For BPC-157 specifically, see Is BPC-157 legal in Japan?.
Article 14 of the PMD Act requires the Minister of Health, Labour and Welfare's approval, product by product, before a medicine is manufactured and marketed in Japan, and importing medicines as a business is limited to licensed marketing-authorisation holders and manufacturers. The MHLW (Ministry of Health, Labour and Welfare) supervises PMDA. The framework is mature and well-enforced — Japan's pharmaceutical regulatory system has been one of the most strict in the world since the post-thalidomide reforms of the 1960s. The combination of MHLW + PMDA + Japan Customs creates a multi-layer barrier to non-approved pharmaceutical imports.
Research peptides — BPC-157, TB-500, GHK-Cu, Selank, Semax, Epithalon — are not approved by PMDA. They have no shouhin code and no place in the Japan Pharmacopoeia. An individual may import medicines for their own use after a customs check within set quantities: one month's supply at the labelled dosage for prescription drugs and poisonous or powerful drugs, 24 standard-size units per item for external-use products, and two months' supply for other medicines (MHLW). Above those quantities the importer needs an import confirmation certificate (輸入確認証) from a Regional Bureau of Health and Welfare, filed with a product description and a copy of a doctor's prescription or instructions (MHLW guideline). The certificate replaced Yakkan Shoumei on 1 September 2020. The listed documents do not include proof that the product is approved in another country, and MHLW's guidance does not say which quantity category applies to a research-labelled peptide.
PeptideGuide found no Japanese official statement on how shipments declared as research chemicals are treated, and has no official or verifiable data on how often parcels from any origin, courier or vendor clear Japanese customs. None of the 4 JP-tracked vendors currently carries a vendor-level warning flag, but the same import rules apply to all of them.
For institutional researchers, MHLW's import-confirmation guideline sets the route: importing unapproved medicines for testing and research (quality, pharmacology or formulation tests) needs import confirmation, filed with a research plan (試験研究計画書), the invoice and the air waybill. Clinical trials (治験) are separate: the trial plan must be notified to the Minister in advance under Article 80-2(2) of the PMD Act.
For non-institutional researchers, the personal-use rules apply: the medicine must be for the importer's own use, within MHLW's quantity limits, with an import confirmation certificate above them. PeptideGuide has no data on how often parcels from any origin or courier are stopped, and does not endorse non-compliant import.
The 4 JP-tracked vendors all maintain research-use-only labelling. None currently carries a vendor-level warning flag, but PMD Act enforcement and customs interception risk apply to every JP-bound shipment. The full vendor reviews flag the customs reality and let researchers self-screen. PeptideGuide methodology weights "regional fulfilment" (which captures JP customs experience) at 15% of vendor composite score.
✓Pros
- MHLW publishes its import-confirmation guideline, including the research-import route for institutions
- Imports within MHLW's personal-use quantity limits need no certificate
×Cons
- Strictest pharmaceutical-import framework among major English-speaking research markets
- Personal imports above MHLW quantity limits need an import confirmation certificate and a doctor's prescription or instructions
- No JP-domestic vendors — all imports cross-border with attendant PMD Act exposure
- Customs risk applies to all 4 JP-tracked vendors, though none currently carries a vendor-level warning flag
- JPY pricing not offered by any tracked vendor — FX friction
Are research peptides legal in Japan?
Research peptides without Japanese approval are unapproved medicines wherever they fall within the PMD Act's definition, so they cannot lawfully be sold or advertised as medicines in Japan. Individuals may import medicines for their own use within MHLW quantity limits; above them an import confirmation certificate is needed (MHLW). PeptideGuide found no official statement on how a research-use-only label is treated. For BPC-157 specifically, see Is BPC-157 legal in Japan?.
What is Yakkan Shoumei?
Yakkan Shoumei (薬監証明) was the earlier certificate for importing unapproved medicines. MHLW states that from 1 September 2020 an import confirmation certificate (輸入確認証) is obtained in its place. The certificate is needed above one month's supply for prescription drugs or two months' for most other medicines, and the application includes a copy of a doctor's prescription or instructions; the listed documents do not include proof of approval abroad (MHLW guideline).
Will Japan Customs intercept my peptide shipment?
PeptideGuide has no official or verifiable data on how often parcels from any origin, courier or vendor clear Japanese customs. Above MHLW's personal-use limits, customs needs an import confirmation certificate at the import declaration (Japan Customs). None of the 4 JP-tracked vendors currently carries an explicit customs warning flag.
What about institutional research?
MHLW's import-confirmation guideline covers it: importing unapproved medicines for testing and research needs import confirmation filed with a research plan (試験研究計画書) (MHLW guideline). Clinical trials (治験) are separate and must be notified to the Minister in advance under PMD Act Article 80-2(2).
Are there any JP-domestic peptide vendors?
No — there are currently no JP-domestic research peptide vendors that PeptideGuide tracks. All JP-bound shipping is cross-border (UK, US, China origins).
What if my shipment is intercepted?
Above the personal-use limits, medicines need an import confirmation certificate, which must be shown to customs at the import declaration (Japan Customs). PeptideGuide has no official source on deadlines or on what happens to a held parcel.
Should I worry about Japanese / English language barriers?
All JP-tracked vendors operate in English. Japanese-language vendor support is rare. For Japanese-only researchers, this creates friction; bilingual researchers have effectively the same options as global English-only buyers. PeptideGuide's Japan edition (jppeptideguide.com) is also published in English.
More from this region.
Other articles covering this region's vendors, regulatory framework, and research peptides.
- 2026-10-31Earlier versions counted 6 JP-tracked vendors and said one carried a warning flag. QSC Peptides, the flagged vendor, was removed after its store went offline in October 2026; 4 vendors are tracked and none currently carries a vendor-level warning flag.
- 2026-10-13Earlier versions called UK-origin vendors the lowest-friction path for individual buyers. PeptideGuide holds no data comparing origins; the claim was removed.
- 2026-10-08Earlier versions said Japan Customs keeps lists of overseas peptide vendors, that UK-origin vendors have the best customs track records and clearance rates, and that misdeclaration is treated more seriously than honest declaration. PeptideGuide found no source for these claims and removed them.
- 2026-10-07Earlier versions called the PMD Act "Yakuhin Iyakuhinrei", described Yakkan Shoumei as the current personal-import certificate with a general two-month limit and a requirement that the product be approved abroad, named Clinical Trial Notification as the route for institutional research imports, and said enforcement against individual buyers is rare. MHLW replaced Yakkan Shoumei with the import confirmation certificate (輸入確認証) on 1 September 2020; the limits are one month's supply for prescription drugs and two months' for most other medicines; MHLW's listed application documents do not include proof of approval abroad; and laboratory research imports need import confirmation with a research plan, while Clinical Trial Notification covers clinical trials. The text was corrected and official sources were linked.